Safety and Efficacy of Treatment With the Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Atherosclerotic Disease: 12 and 24-Month Outcome of the T.I.N.T.I.N. Physician-Initiated Trial.

Background: There is evidence that the treatment of symptomatic femoropopliteal disease with a drug-coated balloon (DCB) effectively inhibits restenosis. However for longer and more complex lesions, "bailout" remains stenting almost inevitable. Although the combination therapy of DCBs and modern bare metal stent (BMS) has not been widely studied, there are indications that this combination therapy is doing better than BMS alone and could be a potential alternative for drug-eluting stent treatment.

Clinical evaluation of quality of life: a survey among members of European Society of Thoracic Surgeons (ESTS).

Objectives: Quality of life (QoL) has been recognized as an important postoperative outcome. Despite the growing interest in this topic, there is almost no information about the daily use of QoL questionnaires within European Society of Thoracic Surgery (ESTS). The aim of this paper is to present the results of a survey launched to know the current practice of collecting and using QoL data within the Society.

Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases.

Introduction: The 5-year overall survival rate of patients undergoing complete surgical resection of pulmonary metastases (PM) from colorectal cancer (CRC) and sarcoma remains low (20-50%). Local recurrence rate is high (48-66%). Isolated lung perfusion (ILuP) allows the delivery of high-dose locoregional chemotherapy with minimal systemic leakage to improve local control.

Surgical treatment of early-stage non-small-cell lung cancer.

Surgical resection remains the standard of care for functionally operable early-stage non-small-cell lung cancer (NSCLC) and resectable stage IIIA disease. The role of invasive staging and restaging techniques is currently being debated, but they provide the largest biopsy samples which allow for precise mediastinal staging. Different types of operative procedures are currently available to the thoracic surgeon, and some of these interventions can be performed by video-assisted thoracic surgery (VATS) with the same oncological results as those by open thoracotomy.

Quality of life evolution after pulmonary metastasectomy: a prospective study comparing isolated lung perfusion with standard metastasectomy.

Objective: To prospectively evaluate quality of life (QoL) evolution after a classic pulmonary metastasectomy or after an isolated lung perfusion (ILuP) metastasectomy.

Methods: QoL was prospectively recorded in 35 consecutive patients (27 classic metastasectomy; 8 ILuP) The European Organisation for Research and Treatment of Cancer C30 and lung cancer -13 QoL Questionnaires were administered before surgery and 1, 3, 6 and 12 months postoperatively (MPO).

Results: After a classic metastasectomy, a temporary increase in dyspnea (1 MPO p = 0.

Subjective and objective assessment of quality of life after chest wall resection.

Objective: To date, quality of life (QoL) after extensive chest wall resection is not known. This study analyses QoL in long-term survivors after extensive resection.

Methods: Retrospective analysis of 51 patients operated for non-small-cell lung cancer (NSCLC)/mediastinal tumour invading the chest wall, primary/secondary chest wall tumours.

Gastrostomy complications in infants and children: a comparative study.

Purpose: Gastrostomy is a commonly undertaken procedure in children. Methods for gastrostomy insertion have evolved and laparoscopy is commonly used to aid its insertion. The aim of this study is to review the outcome and complications of laparoscopic-assisted gastrostomy insertion.

Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?

Background: Debate remains about the relative prognostic importance of the histologic subtype of malignant pleural mesothelioma.

Methods: From a prospective database, the details of 312 malignant pleural mesothelioma surgical patients were reviewed. A comparison was made of the survival from the three major cell types.

Quality of life evolution after lung cancer surgery in septuagenarians: a prospective study.

Objective: To prospectively evaluate quality of life (QoL) evolution after lung cancer surgery in a cohort of septuagenarians with the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and LC13.

Methods: Between January 2003 and December 2006, QoL was prospectively recorded in 60 consecutive septuagenarians undergoing lung cancer surgery. Forty-nine lobectomies and 11 pneumonectomies were performed.

Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy.

Objective: To prospectively evaluate quality of life (QoL) evolution after sleeve lobectomy and pneumonectomy with the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and LC-13.

Methods: From January 2003 till December 2005, QoL was prospectively recorded after 10 sleeve lobectomies and 20 pneumonectomies. Questionnaires were administered before surgery and 1, 3, 6, and 12 months postoperatively (MPO) with response rates of 100%, 90.

Quality of life evolution after surgery for primary or secondary spontaneous pneumothorax: a prospective study comparing different surgical techniques.

The objective of the present study is to evaluate quality of life (QoL) evolution after video-assisted thoracic surgery (VATS) and anterolateral thoracotomy (AT) for primary and secondary spontaneous pneumothorax, which has not been studied prospectively until now. From January 2003 to December 2004, QoL was prospectively recorded in 20 consecutive patients, using the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and the lung specific module LC-13. Questionnaires were administered before surgery and 1, 3, 6 and 12 months postoperatively (MPO) with response rates of 100%, 85%, 80%, 65% and 60%, respectively.